The Clinical Division of Nephrology and Dialysis is currently conducting a randomized trial to define further SARS-CoV-2 vaccination protocol in kidney transplant recipients.
The study is entitled: A single-blind randomized controlled trial of BNT162b2 or mRNA-1273 (mRNA) versus Ad26COVS1 (viral vector) in kidney transplant recipients without evidence of antibodies to the SARS-CoV-2 spike protein after complete vaccination against COVID-19 (Boost-TX).
Current data show that kidney transplant patients develop a protective immune response (antibodies) against coronavirus in less than half of the cases after complete vaccination. A third vaccination increases the likelihood of developing a protective immune response. However, it is currently unclear whether further vaccination with the same vaccine or switching to a different vaccine group (heterologous vaccination) increases the likelihood of response and will be answered by this study.
Since immunocompromised patients as a risk group in Austria have usually received vaccination with an mRNA vaccine so far, patients after kidney transplantation who did not develop antibodies against the spike protein of the SARS-CoV-2 virus after complete immunization (two administrations of an mRNA vaccine) at least four weeks after the 2nd vaccination were invited to the study. Currently, 200 patients are participating in the study. They have now received either a single dose of the Johnson & Johnson vector vaccine or a repeat dose of the previously received mRNA vaccine (Biontech or Moderna) as part of the study.
In the first two weeks of August, the vaccination response of the study participants will again be measured on the basis of the antibodies formed and the cellular immunity against the SARS-CoV-2 spike protein, and the first results of the study can be expected before the end of August. These results will have a far-reaching impact on further vaccination procedures in this patient group.